AGN 2.70% 76.0¢ argenica therapeutics limited

Great article in AFR today with SG Hiscock :What’s a stock you...

  1. 9,854 Posts.
    lightbulb Created with Sketch. 980
    Great article in AFR today with SG Hiscock :

    What’s a stock you like that (most) investors wouldn’t have heard of?

    We think Argenica Therapeutics, while still at an early stage, has IP which is showing huge promise. Their lead asset, ARG-007, is a neuroprotective peptide designed to protect brain cells and reduce cell death following strokes and other acute brain injuries.

    The company is currently conducting a phase two clinical trial of ARG-007 for acute ischemic stroke in multiple hospitals across Australia. The trial will evaluate the safety and efficacy of the asset in reducing brain cell death and improving patient outcomes.

 
watchlist Created with Sketch. Add AGN (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.